Stem cell approaches in psychiatry - challenges and opportunities by Benninghoff, Jens
egenerative medicine appears to be on the
brink of a bonanza in terms of new treatment options, ie,
stem cell-based therapy. Up to now, stem cell-based
interventions (SCBI) have still been in an immature
state. Only a few trials are currently under way, and are
so far mostly in a preclinical phase. Current focuses
include Duchenne’s disease, Parkinson`s disease, and
Alzheimer’s disease.
1 The major concept of all these
experiments is to create a treatment scheme similar to
that in bone-marrow diseases where hematopoietic stem
cells are regularly used as a cure for certain types of
leukemia—in this case, the issue of the appropriate stem
cell type used has been solved. For SCBI in neurode-
generative disease there is an ongoing debate regarding
which cell type might be suitable for transplantation—
embryonic versus fetal versus adult stem cells.
Furthermore, the question of stem-cell homing needs to
be addressed, since one may not need to transplant the
cells by neurosurgical procedures. Instead, it could be
sufficient to inject these cells into the cubital vein only,
2
since the plasticity of these cells enables them to find the
niche where they are needed—even within the central
nervous system (CNS). 
Apart from technical aspects, ethical problems arise.
Even without touching on the debate of using human
embryonic stem cells, there is plenty of groundwork for
bioethicists to do. 
When the ethical and technical issues have been resolved,
we may proceed from neurodegenerative to psychiatric
illnesses such as affective disorders and schizophrenia. 
We still face a substantial lack of proof as to whether
these psychoses are the cause or the correlate of dis-
turbed adult neurogenesis.
3 If so, we may consider these
severe illnesses as being neurodegenerative, as there is
some compelling data for this, at least in the field of
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Exploring stem cells is a fascinating task, especially in a dis-
cipline where the use of stem cells seems far-fetched at first
glance, as is the case in psychiatry. In this article we would
like to provide a brief overview of the current situation in
relation to the treatment of mental diseases. For reasons
that we will explain, this review will focus on affective dis-
orders. The following section will give a more detailed
account of stem-cell biology, including current basic science
approaches presenting in-vivo and in-vitro techniques. The
final part will then look into future perspectives of using
these stem cells to cure mental illnesses, and discuss the
related challenges and opportunities. 
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DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 397depression. There may be some clinical trials of graft-
ing stem cells, in a long and cumbersome process, into
the brains of diseased patients. In our opinion, this will
only be the case for very severe cases of depression,
after having tried nearly all the available medication
options and unsuccessful electroconvulsive therapy
(ECT). 
Past and current status
In the past, psychiatric diseases have been treated phar-
macologically with broad-profile medication—the so-
called “shotgun method.” In the same way that a shotgun
fires many pellets at once, psychiatric medication can
impact on many different neurotransmitter systems. Due
to this profile, many of these drugs, such as tricyclic anti-
depressants (TCAs) or first-generation antipsychotics
(FGAs) caused severe undesirable side effects, which
were held responsible for poor compliance and discon-
tinuation of the prescribed medication.
During the last two decades, new drugs have surfaced
with fewer shotgun side effects because of their particu-
lar pharmacodynamic design targeted against one single
and very specific molecule. In this context, selective sero-
tonin reuptake inhibitors (SSRIs) should be mentioned
here as an example of an antidepressant agent acting
solely on one neurotransmitter system and within the
serotonergic system on one distinct transporter molecule.
The same holds true for second-generation antipsychotics
(SGAs) displaying only few side effects due to less rigid
inactivation of dopamine receptor type 2 (DR2) and
therefore fewer extrapyramidal motor symptoms recall-
ing parkinsonism.
Nevertheless, we are still struggling with inefficacious
medication, since only about one third of antidepres-
sant agents work in a given patient, meaning that one
has to try on average three different medications in
order to alleviate this patient`s symptoms. For schizo-
phrenia the same holds true. Sometimes, the individual
situation seems even worse than in the field of affective
disorders. 
Some stem cell basics
As mentioned above, this article emphasizes the link
between disturbed adult neurogenesis (AN) and affec-
tive disorder. The case seems to be much more evident
here than in schizophrenia, although decreased neural
stem cell proliferation in the dentate gyrus (DG) of the
hippocampus has been demonstrated in postmortem
human brain from schizophrenic patients.
4
Stem cells can be characterized by two fundamental qual-
ities: first, they have the capacity for unlimited self-
renewal, and second, they can produce at least one type
of highly differentiated descendants.
5This particular cell
division is termed “asymmetrical”: in general, each stem
cell division gives rise to one stem and one committed
somatic daughter cell.
6 Stem cells are single cells that,
once developed, self-renew for the lifetime of the organ-
ism. These stem cells should be distinguished from tran-
sient progenitor cells, which have a limited self-renewal
lifespan.
7 Some steps earlier during the embryonic period,
cells become gradually restricted to distinct pathways of
differentiation. This process includes modification of their
developmental potential; they become pluripotent
(“many, several”). The major difference between totipo-
tency and pluripotency is that an embryonic stem cell (ES
cell) which is by definition “pluripotent,” can only form
cells which constitute the embryo itself but not the pla-
centa. Early ES cells can be taken from the embryo and
grown in vitro. When retransferred into the embryo, these
cells can still generate all tissues, including the germ line.
8
ES cells also play a central role in the generation of trans-
genic animals such as knockout mice.
Pluripotency of stem cells becomes progressively
restricted and they become multipotent. Multipotent
stem cells in the brain ultimately give rise to all different
types of neuronal and non-neuronal cells in the central
nervous system. Presumably they have lost the ability to
produce cells of ento- and mesodermal origin. Because
they are capable of generating the entire progeny of a
given tissue, some investigators have termed these mul-
tipotent stem cells “progenitor cells.” Moreover, there is
controversy as to whether neural stem cells can actually
remain viable during the entire lifespan.
9
Adult forebrain neural stem cells were discovered in
1992
10 in the adult remnant of the embryonic brain ger-
minal zone surrounding the lateral ventricle. Evidence for
their participation in repopulating the adult lateral ven-
tricular subependyma following irradiation
11 led to the
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DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 398hypothesis that neural stem cells also exist after the
embryonic and fetal period, similarly to hematopoietic
stem cells. Hematopoietic stem cells in adult animals can
restore different blood cell types. For a long time it has
been thought that once a cell had been programmed to
produce a particular tissue, its fate was sealed and it could
not reprogram itself to form another tissue. Contrarily to
this view, reactivation of dormant genetic programs
appears to work under certain circumstances. Intriguingly,
stem cells from brains of adult mice have been shown to
possess the potential to become functional blood cells.
12
Similar results for the inverse case were reported, ie, mul-
tipotential mesenchymal cells transformed into neural
cells—astrocytes in this case.
13
According to Fred H. Gage, the term “neural stem cell”
should therefore be used with caution to describe cells
that “a) generate neural tissue, b) are capable of self-
renewal, and c) give rise to cells other than themselves
through asymmetric cell division.”
14 In fact, when the
issue of lineage specificity of adult neural stem and prog-
enitor cells is considered, there is abundant reason for
caution regarding the term neural stem cell. The ability
of bone marrow stem cells to generate astrocytes,
13 the
finding that astrocyte-like cells in the subependyma are
neural stem cells,
15,16 and that oligodendrocyte-precursors
contribute neural stem cell-like cells
17—all these findings
soften the theoretical distinction between stem and prog-
enitor cells. All this makes it really difficult to decide
which type of stem cells one should use for transplanta-
tion. Even during the process of grafting stem cells they
can still start to differentiate and become more restricted
progenitors due to cell-cell contacts or influence of adhe-
sion inside the syringe. 
Further, neural stem cell research suffers dearly from the
lack of an antibody specifically identifying neural stem
cells. Detecting stem cells ad hoc and not ex post remains
a problem. Putative stem cells need to differentiate into
their derivative neural cell subpopulations before one
can positively identify them as regular neural stem cells.
In the past, efforts to generate antibodies against adult
stem cells did not prove sustainability.
18,19There are cer-
tain advantages of adult over embryonic stem cells in that
the former may be easier to manage. ES cells tend to dif-
ferentiate spontaneously into all kinds of specified tissue.
For example, when injected subcutaneously into
immunocompromised mice they grow into teratomas,
tumors consisting of numerous cell types ranging from
gut to skin. Before applying these cells in humans, gen-
eration of the desired cell types should therefore be
ensured without undesired side effects or unwanted cell
populations, respectively. Here, it seems that adult stem
cells are better behaved, since they do not differentiate
spontaneously.
Instead this can be induced by applying appropriate
growth factors. However, adult stem cells have a differ-
ent drawback, in that they seem to lose their ability to
divide and differentiate after some time in culture.
Maybe in the end ethical considerations will also con-
vince the scientific community to follow the adult stem
cell rather than the ES cell track. Compared with embry-
onic or fetal stem cells, adult stem cells pose fewer ethi-
cal problems because they can be obtained from sources
other than embryos or aborted fetuses.
20 Even post-
mortem human tissue can yield neural stem cells.
21 In
consensus with Frank E. Young
22 the public, as well as
governmental authorities, should enter the process of
unbiased dialogue, in order to establish the principles
according to which research needs to be conducted. 
As of now, we should consider the human species an appro-
priate source for SCBI. Having said this, we should take
into account possible chimerae of animals with human cells
in their brains, and above all with possible human behav-
ior.
23Another issue to be ruled out is to prevent striking
behavioral traits after SCBI. In Parkinson’s disease patients
it has been shown that after L-Dopa treatment some
patients responded with pathological gambling,
24 since
dopamine sustains the reward system. One could easily
imagine a scenario like this in a patient after SCBI. In this
case, it might not be as easy to lower the dopamine pro-
duction as it is with cessation of the medication. 
As mentioned above, grafting hematopoietic stem cells
has already become a conventional clinical tool in the
treatment of certain types of leukemia. Currently it can
only be hypothesized that transplantation of neural stem
cells has potential for treating brain disease.
25
Although all these obstacles do exist, the main target for
the research on neural stem cells must be to restore reg-
ular neural function in areas where cells have died or lost
their physiologic behavior. Clinicians are eager, for exam-
ple, to transplant NSCs into patients suffering from
Parkinson’s disease,
26 multiple sclerosis, or spinal cord
injuries, although it is not clear so far which is the appro-
priate cell to transplant—the CNS neural stem cells, the
actual neurons, or intermediate progenitors between the
two. Thus, in neurodegenerative diseases it is important
to first determine the rules of transplantation of stem,
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DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 399progenitor, and mature cells, as well as to determine the
sites into which the transplants must be located. In
Parkinson’s disease we do not know whether cells should
be placed into the substantia nigra, or striatum, or both.
So we continue wondering which particular region of the
abovementioned brain areas should be chosen—eg, the
ventral part or the dorsal putamen in only one hemi-
sphere or both. The variability in surgical methods
between centers which perform stem cell transplantation
makes it very difficult to assess the results of this proce-
dure.
26 Still, if we get to the point where all these issues
are resolved, we will have to find better ways to secure
the long-term survival of the grafted cells.
So far, the de novo generated dopaminergic neurons
have only a limited lifespan in animal studies.
27 Finally,
the source of the cells should be clarified, since we need
huge amounts of human fetal tissue for transplantation.
Although there has been much progress achieved over
the last few years, especially in long-term proliferation
and dopaminergic differentiation of progenitor cells,
28 we
still have to invest much effort in finding alternative
methods, such as in vivo mobilization of dormant neural
stem cells, which seems to be a more useful concept.
Pathophysiologic models of depression
In the light of recent findings such as loss of total cell vol-
ume in certain brain areas observed in depressed patients
(see below), we can heretically define depression as a
“neurodegenerative” disease. As we will discuss, this par-
ticular illness does not necessarily require stem cell trans-
plantation. Instead, it may be possible to replenish miss-
ing neurons by regulating the microenvironment
surrounding the putative sites of neural stem cells where
neurogenesis takes place. Lessons from recent findings
in pathophysiology might open up a broad research
avenue with the ultimate goal of treating depression.
In a WHO survey, depression and manic-depressive ill-
ness will still rank among the top 10 causes for death in
the year 2010. Certainly not all forms of depression even-
tually lead to death by suicide, but even milder courses
of this illness may lead to severe incapacitation of mil-
lions of people worldwide. In particular, it impairs rein-
tegration into their familiar social environment and into
the working process. Accumulating evidence from neu-
robiology suggests that distinct biochemical processes are
derailed in a large number of depressed subjects. Cellular
and molecular adjustments following stress seem to play
key roles in onset and propagation of mood disorders. To
most of us, stress is a beneficial response of our neuronal
systems to acute challenges of the exterior world. To put
it simply, it is more beneficial for a rabbit to become
stressed and flee when it sees a fox approaching.
However, severe or repeated stress can lead to detri-
mental effects on regular neural function.
29
Neural plasticity is a term which involves interneuronal
communication and adaptation in order to give the
appropriate responses to stress or aversive stimuli. One
example of such a response could be changes in neuro-
genesis—the generation of new neurons. Dysfunction of
adequate regulatory processing due to severe or chronic
stress is capable of disturbing neural plasticity.
Medical treatment with antidepressant agents may bring
back regular function of neural systems by influencing
neural plasticity: antidepressants require long-term
administration, while blockade of the reuptake of sero-
tonin (5-HT) and/or norepinephrine as their most com-
mon and initial mode of action is fairly rapid. There is a
process whereby neurons can adapt to and regain plas-
ticity while the local biochemical environment is chang-
ing due to the application of antidepressants. Thus, the
long-term mode of action of antidepressant medication
seems much more dynamic and complex than just up- or
downregulation of synaptic levels of monoamines.
The role of the hippocampus
The hippocampus is a well-characterized brain structure.
In 1886 C. Golgi stained hippocampal neurons with his
novel silver impregnation technique, which became
known as the Golgi procedure. Since then a great num-
ber of neuropsychiatric phenomena have been studied in
the hippocampal formation.
The relatively simple organization—pyramidal neurons
in the hippocampus proper and the granule cells of the
dentate gyrus are arranged in single, densely packed cell
layers—is one of the major reasons why the hippocam-
pus has frequently been used as a cytoarchitectural
model of the cortex. Recent findings in volumetric neu-
roimaging studies make a strong case that biochemical
changes in the brain carry morphological sequels. So far
we have learned that gray matter volumes are diminished
in depressed patients and in post-traumatic stress disor-
der patients in the medial and orbital prefrontal cortex,
the mesiotemporal cortex, and the ventral striatum, and
are accompanied by an enlargement of the third and the
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30-33 Hippocampal gray matter volume is
reduced strikingly in depressed patients.
34,35
Additional postmortem brain studies underpin the above-
mentioned results. According to Vincent et al
36 there is a
layer-specific reduction of interneurons in the anterior cin-
gulate cortex. Significant reduction in numbers of non-
pyramidal neurons in the CA2 area of hippocampus was
reported in postmortem studies of bipolar disorder.
37Also
in regions other than hippocampus, there may be a decline
in brain region volume and total cell number.
38,39
Elevation of cortisol levels in the elderly correlates with
reduced hippocampal volume, and is associated with
memory deficits.
40
Patients with depression have a functional deficit of the
hypothalamic-pituitary-adrenal (HPA) axis.
41 Hippocampal
neurons are reported to be damaged by exposure to stress
or activation of the HPA axis and elevation of glucocor-
ticoids. Taken together, this overview of morphologic evi-
dence strongly supports a functional link between changes
at the molecular levels and morphology. The task of future
research could be to develop strategies allowing the dis-
eased hippocampus or other affected brain structures to
regain regular morphology and function. Focusing on neu-
rogenesis—which is defined as a series of events including
proliferation of a neural precursor or stem cell that results
in appearance of a new neuron
42—may be a systematic as
well as pragmatic way to proceed.
There is a growing body of evidence for the phenomenon
of neurogenesis in humans.
15 Localization of pluripotent
progenitor cells and thus neurogenesis appears to be
restricted to certain brain regions, in particular, the sub-
ventricular zone (SVZ) and the subgranular layer of the
dentate gyrus of the hippocampus.
42 Neurogenesis in the
adult mammalian brain is regulated by genetic and envi-
ronmental factors
43-45—all leading to the exciting possi-
bility of pharmacological regulation of neurogenesis in
the adult brain, and eventually of the disease-related
pathophysiological changes.
One of the mainstay therapies in the treatment of recur-
rent mood disorders, lithium, ranks among such pharma-
cologic candidates. Lithium increases the levels of the
antiapoptotic protein bcl-2.
46,47We now know that besides
its role in cell cycle control, bcl-2 functions as a neu-
rotrophic factor, since bcl-2 promotes axon regeneration
as well as neurite and axonal outgrowth.
48 In general,
neurotrophic factor signaling is mediated both by the
phosphatidyl-inositol-3-kinase pathway and activation of
the MAP (mitogen-activated kinase) cascade.
49,50
Activation of MAP cascade augments bcl-2 expression.
This is very likely to involve the cAMP responsive ele-
ment binding protein (CREB).
51
CREB is attractive to many researchers because it
appears in some way required for long-term memory.
52
CREB may increase the integrity and functional plastic-
ity of granule cell neurons assuming that CREB is a crit-
ical determinant of neural plasticity as well as cell sur-
vival. One putative gene target of CREB—and thus of
chronic antidepressant treatment—is brain-derived neu-
rotrophic factor (BDNF). There is a functional cAMP
responsive element in the exon III promoter of the
BDNF gene.
53 In the light of this, it is not surprising that
local infusion of BDNF in the hippocampus produces an
antidepressant effect.
54
In vitro, activation of the cAMP system upregulates
BDNF expression in hippocampal cells.
55,56Additionally,
BDNF expression effects neuronal depolarization and
activation of voltage-dependent calcium channels. These
alterations at the synaptic level underlie the influence of
BDNF on long-term potentiation.
57This underscores the
central role of BDNF in neurogenesis considering the
pivotal role attributed to BDNF in lineage differentia-
tion of neural stem cells.
Another key player in the pathophysiology and treat-
ment of depression, the biogenic amine 5-HT, should not
be neglected, since 5-HT is one of the most extensively
studied neurotransmitters of the central nervous system.
Moreover, novel findings indicate that 5-HT is particu-
larly relevant to neurogenesis in the hippocampus
(Figure 1), because in adult rats it has been shown that
decreased 5-HT lowers the rate of neurogenesis in the
dentate gyrus of hippocampus.
58 Historically, 5-HT was
first described as a serum component augmenting
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Figure 1. A) Putative model of the serotonergic (5-HT) machinery in adult
neural stem cells. Tryptophan hydroxylases (TPH) produces 5-HT,
which controls its own metabolism mainly via 5-HT1A and 5-
HT2C receptors. B) TPH inactivation leads to less 5-HT produc-
tion—model proposed by the author based on own experi-
mental data (Benninghoff et al, unpublished data).
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59 In such non-neural systems,
5-HT has been a potent mitogen.
60,61
In the brain, 5-HT is among the most widely distributed
neurotransmitters. All serotonergic fibers originate in the
brain stem raphe nuclei. By way of extensive synaptic
connections of the serotonergic fibers, 5-HT contributes
to many physiologic functions such as endocrine and cir-
cadian rhythms, food intake, sleep, reproductive activity,
and motor function, as well as cognition, mood, and anx-
iety.
62 In the brain we currently know of 16 different
cloned receptor types and subtypes, but it can be
expected that their number will grow even further in the
near future. In contrast to the multitude of 5-HT recep-
tors, there is only a single 5-HT transporter (5-HTT)
responsible for the reuptake of 5-HT into serotonergic
neurons after its release into the synaptic cleft. As our
own studies have shown, 5-HTT does not have a large
impact on neurogenesis.
63
A possible role for 5-HT as direct mediator of granule cell
generation is currently discussed, since elevated 5-HT lev-
els in the hippocampus increase the rate of proliferation
of granule cell precursors.
64 Epidermal growth factor
(EGF) is believed to exert an essential function on the
generation and maintenance of neural stem cells. It is
therefore not surprising that in non-neural systems, EGF
and 5-HT can augment the rate of cell proliferation in a
synergistic manner.
65 BDNF again seems involved in medi-
ating the effects of 5-HT. Thus, chronic administration of
5-HT-selective reuptake inhibitors, clinically used as anti-
depressants, leads to upregulation of BDNF mRNA.
56
As already mentioned above, 5-HT exerts its action
through a large family of receptors in the periphery and
throughout the CNS.
62 A possible role for the 5-HT1A
receptor in the modulation of anxiety and depression, as
well as in the mode of action of anxiolytic and antide-
pressant drugs, has been suspected for many years.
66 5-
HT1A receptors operate both as somatodendritic autore-
ceptors and postsynaptic receptors. Research regarding
5-HT1A receptor has shown
67 that the effect of antide-
pressants upregulating extracellular serotonin levels
worked via the 5-HT1A receptor subtype, thus opening
a link between our in vitro system, neurogenesis, and clin-
ical relevance in terms of affective disorders. 
Althogh the serotonin hypothesis of depression
68 is very
attractive in this regard, it should not be omitted here
that there are additional compelling findings dealing with
other neurotransmitting systems, eg, supporting cholin-
ergic mechanisms.
69 Riederer et al
70 came to the conclu-
sion that a brain area-specific imbalance of neurotrans-
mitters leads to the clinically different manifestations of
depression. The loss of regional interneuronal home-
ostasis must not necessarily affect huge brain areas; it
might be only limited to certain small and circumscripted
regions in the brain. As a consequence, clinicians should
be able to choose the pharmacologically appropriate
medication for the affected brain region.
71
Concluding remarks
Stem-cell maintenance and generation take place in a
distinct microenvironment where appropriate external
signals can best exert their regulatory function on these
cells. Signals provided by neural growth factors are
responsible for neural stem-cell growth. Since compo-
nents of regular stem-cell maintenance like BDNF are
also implicated in mechanistic models characteristic of
mood disorders, they thus offer new targets for pharma-
cologic intervention in neuropsychiatric disease. More
thorough knowledge about this complex connection may
help us render antidepressant treatment more efficient
and reduce the undesirable side effects that impair
patient compliance. So far there is no stem-cell-based
approach really on the horizon for treating depression or
any other psychosis.  ❏
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Acercamiento a las células madre en 
psiquiatría: desafíos y oportunidades
La exploración de las células madre es una tarea fas-
cinante, especialmente en una disciplina donde el
empleo de ellas parece exagerado a primera vista,
como es el caso de la psiquiatría. En este artículo se
quiere entregar una breve panorámica de la situa-
ción actual en relación con el tratamiento de las
enfermedades mentales. Por razones que serán expli-
cadas, esta revisión se centrará en los trastornos afec-
tivos. La sección siguiente dará cuenta más detallada
de la biología de las células madre, incluyendo las
propuestas actuales de la ciencia básica que se pre-
sentan en técnicas tanto in-vivo como in-vitro. La
parte final se orientará hacia las perspectivas futuras
del empleo de estas células madre para la cura de las
enfermedades mentales, y se discutirán los desafíos
y oportunidades relacionadas con ellas.  
Approches des cellules souches en 
psychiatrie : défis et perspectives
Explorer les cellules souches est passionnant, sur-
tout dans un domaine comme la psychiatrie où, au
premier abord, leur utilisation semble incongrue.
Cet article souhaite offrir un aperçu de la situation
actuelle en rapport avec le traitement des maladies
mentales et, pour des raisons qui seront données
ultérieurement, il ne traitera que des troubles de
l’humeur. La première partie détaillera la biologie
des cellules souches, y compris les approches scien-
tifiques actuelles des techniques in vivo et in vitro.
Ensuite,  les perspectives d’utilisation des cellules
souches dans le traitement des maladies mentales
seront présentées et  les défis et opportunités qui y
sont liés seront discutés.
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